ABCMdb

PMID: 18681776

Cusatis G, Sparreboom A
Pharmacogenomic importance of ABCG2.
Pharmacogenomics. 2008 Aug;9(8):1005-9., [PubMed]

Sentences

No. Mutations Sentence Comment

24 ABCG2 p.Gln141Lys In particular, a SNP in exon 5 of the ABCG2 gene has been described, in which a 421C>A transversion results in a lysine to glutamine amino acid change at codon 141 (Q141K) [12]. Login to comment 27 ABCG2 p.Val12Met ABCG2 p.Ile206Leu ABCG2 p.Asn590Tyr Several other SNPs have been identified in coding regions of the gene, and at least three additional nonsynonymous SNPs have been identified, occurring at positions 34 (V12M, exon 2), 616 (I206L, exon 6) and 1768 (N590Y, exon 15). Login to comment 33 ABCG2 p.Gln141Lys Substrates • 9-aminocamptothecin, abacavir, bisantrene, BNP1350, chlorin E6, CI1033, ciprofloxacin, cladribine, daunorubicin, diflomotecan (BN-80915), dipyridamole, doxorubicin, DX-8951f, edevarone (metabolites), epirubicin, erlotinib, etoposide, flavopiridol, gefitinib, gimatecan, glyburide, GW1843, heterocyclic amines, homocamptothecin, imatinib, J-107088, JNJ-7706621, leflunomide, methotrexate, mitoxantrone, NB-506, nelfinavir, nitrofurantoin, norfloxacin, ofloxacin, olmesartan, pheophorbide A, pitavastatin, posuvastatin, protoporphyrin IX, pyropheophorbide A, SN-38 (irinotecan metabolite), sulfasalazine, teniposide, tomudex, topotecan, triglutamate, UCN-01, zidovudine Inhibitors • 17-β-estradiol, 6-prenlychrysin, abacavir, acacetin, amprenavir, atazanavir, biricodar (VX-710), chrysin, CI1033, curcumin, cyclosporin A, delavirdine, diethylstilbestrol, dihydropyridines, dipyridamole, efavirenz, elacridar (GF120918), estrone, fumitremorgin C (FTC), gefitinib, genistein, ginsenosides, imatinib, Ko143 (FTC analog), lopinavir, naringenin, nelfinavir, nicardapine, nimodipine, nitrendipine, novobiocin, ortataxel, pantoprazole, quercetin, reserpine, ritonavir, rosuvastatin, saquinavir, silymarin, sirolimus (rapamycin), tacrolimus, tamoxifen, tariquidar (XR9576), techochrysin, tryprostatin A, WK-X-34 demonstrated that subjects with a reduced ABCG2 activity owing to the Q141K variant are at an increased risk for gefitinib-induced diarrhea [17] (Figure 1), and altered pharmacokinetics of 9-aminocamptothecin [18], diflomotecan [19], irinotecan [20], rosuvastatin [21], sulfasalazine [22,23] and topotecan [24]. Login to comment